Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff DrugsFDA allowed compounding pharmacies a grace period to cease production post-drug shortage, but some continue to sell modified tirzepatide products.
FDA declares end to Wegovy and Ozempic shortageThe FDA declared an end to the national shortage of Ozempic and Wegovy medications.Novo Nordisk met and exceeded the U.S. demand for semaglutide products.
The Ozempic Shortage Is OverThe FDA has declared semaglutide no longer in shortage, affecting cheaper compounded versions and signaling significant market changes.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is overHims & Hers stock dropped nearly 10% due to FDA lifting drug shortages for competitor Eli Lilly, while its own semaglutide product remains unaffected.
Lilly weight-loss drug copycats dealt blow as shortage endsEli Lilly's medications are no longer in shortage, affecting the market for knockoff versions.The FDA has resolved the shortage of Zepbound and Mounjaro, impacting compounded alternatives.
FDA declares end to Wegovy and Ozempic shortageThe FDA declared an end to the national shortage of Ozempic and Wegovy medications.Novo Nordisk met and exceeded the U.S. demand for semaglutide products.
The Ozempic Shortage Is OverThe FDA has declared semaglutide no longer in shortage, affecting cheaper compounded versions and signaling significant market changes.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly's weight-loss drug shortage is overHims & Hers stock dropped nearly 10% due to FDA lifting drug shortages for competitor Eli Lilly, while its own semaglutide product remains unaffected.
Lilly weight-loss drug copycats dealt blow as shortage endsEli Lilly's medications are no longer in shortage, affecting the market for knockoff versions.The FDA has resolved the shortage of Zepbound and Mounjaro, impacting compounded alternatives.
A Review of Novo Nordisk's Ozempic and Wegovy Trademark Enforcement CampaignAdvertising compounded semaglutide products referencing Novo Nordisk's trademarks raises concerns of consumer confusion.